BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24281041)

  • 1. Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
    Toba H; Wang J; Ohigashi M; Kobara M; Nakata T
    Pharmacology; 2013; 92(5-6):265-75. PubMed ID: 24281041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
    Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
    Nagashima A; Watanabe R; Ogawa M; Suzuki J; Masumura M; Hishikari K; Shimizu T; Takayama K; Hirata Y; Nagai R; Isobe M
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):158-64. PubMed ID: 22561360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
    Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
    Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway.
    Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M
    J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
    Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
    Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
    Tsukuda K; Mogi M; Iwanami J; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
    Hypertension; 2009 Oct; 54(4):782-7. PubMed ID: 19635982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
    Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
    Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
    Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
    Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
    Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
    Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
    Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
    Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
    Wang WW; Zhang FL; Chen JH; Chen XH; Fu FY; Tang MR; Chen LL
    Can J Physiol Pharmacol; 2015 Aug; 93(8):657-65. PubMed ID: 26158699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats.
    Kishi T; Hirooka Y; Sunagawa K
    J Cardiol; 2012 Dec; 60(6):489-94. PubMed ID: 22948091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.